Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Signal Transduction and Targeted Therapy,
Год журнала:
2025,
Номер
10(1)
Опубликована: Март 5, 2025
The
successful
approval
of
peptide-based
drugs
can
be
attributed
to
a
collaborative
effort
across
multiple
disciplines.
integration
novel
drug
design
and
synthesis
techniques,
display
library
technology,
delivery
systems,
bioengineering
advancements,
artificial
intelligence
have
significantly
expedited
the
development
groundbreaking
drugs,
effectively
addressing
obstacles
associated
with
their
character,
such
as
rapid
clearance
degradation,
necessitating
subcutaneous
injection
leading
increasing
patient
discomfort,
ultimately
advancing
translational
research
efforts.
Peptides
are
presently
employed
in
management
diagnosis
diverse
array
medical
conditions,
diabetes
mellitus,
weight
loss,
oncology,
rare
diseases,
additionally
garnering
interest
facilitating
targeted
platforms
advancement
vaccines.
This
paper
provides
an
overview
present
market
clinical
trial
progress
therapeutics,
platforms,
It
examines
key
areas
through
literature
analysis
emphasizes
structural
modification
principles
well
recent
advancements
screening,
design,
technologies.
accelerated
including
peptide-drug
complexes,
new
vaccines,
innovative
diagnostic
reagents,
has
potential
promote
era
precise
customization
disease
therapeutic
schedule.
Язык: Английский
Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity
Communications Biology,
Год журнала:
2025,
Номер
8(1)
Опубликована: Янв. 15, 2025
Abstract
We
have
assessed
antiviral
activity
and
induction
of
protective
immunity
fusion-inhibitory
lipopeptides
derived
from
the
C-terminal
heptad-repeat
domain
SARS-CoV-2
spike
glycoprotein
in
transgenic
mice
expressing
human
ACE2
(K18-hACE2).
The
block
infection
cell
lines
lung-derived
organotypic
cultures.
Intranasal
administration
allows
maintenance
homeostatic
transcriptomic
immune
profile
lungs,
prevents
body-weight
loss,
decreases
viral
load
shedding,
protects
death
caused
by
variants.
Prolonged
high-dose
has
neither
adverse
effects
nor
impairs
peptide
efficacy
subsequent
challenges.
peptide-protected
develop
cross-reactive
neutralizing
antibodies
against
both
used
for
initial
recently
circulating
variants,
are
completely
protected
a
second
lethal
infection,
suggesting
that
they
developed
SARS-CoV-2-specific
immunity.
This
strategy
provides
an
additional
approach
global
effort
COVID-19
may
contribute
to
development
rapid
responses
emerging
pathogenic
viruses.
Язык: Английский
Synergistic peptide combinations designed to suppress SARS-CoV-2
Tao Han,
Linhong Song,
Xinxin Niu
и другие.
Heliyon,
Год журнала:
2024,
Номер
10(9), С. e30489 - e30489
Опубликована: Апрель 29, 2024
The
SARS-CoV-2,
responsible
for
the
COVID-19
pandemic,
poses
a
significant
threat
to
global
healthcare.
Peptide
and
peptide-based
inhibitors,
known
their
safety,
efficacy,
selectivity,
have
recently
emerged
as
promising
candidates
treating
late-developing
viral
infections.
In
this
study,
three
peptides
were
selected
target
different
stages
of
invasion,
specifically
ACE2
S
protein
binding,
well
membrane
fusion.
objective
was
assess
ability
impede
entry
SARS-CoV-2
Spike
pseudotyped
virus.
Our
findings
revealed
that
combination
these
demonstrated
enhanced
antiviral
effects.
This
outcome
substantiates
feasibility
developing
effective
peptide
combinations
combat
diseases
related
SARS-CoV-2.
Moreover,
three-peptide
combinations,
designed
multiple
aspects
entry,
exhibited
heightened
inhibition
broad-spectrum
properties.
Язык: Английский
Characterization of the Pathogenic Features of Multiple SARS-CoV-2 Pandemic Strains in Different Mouse Models
Опубликована: Янв. 1, 2024
Язык: Английский
M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 2, 2024
The
frequent
occurrence
of
mutations
in
the
SARS-CoV-2
Spike
(S)
protein,
with
up
to
dozens
mutations,
poses
a
severe
threat
current
efficacy
authorized
COVID-19
vaccines.
Membrane
(M)
which
is
most
abundant
viral
structural
exhibits
high
level
amino
acid
sequence
conservation.
M
protein
ectodomain
could
be
recognized
by
specific
antibodies;
however,
extent
it
immunogenic
and
provides
protection
remains
unclear.
Язык: Английский
Characterization of the Pathogenic Features of Multiple SARS‐CoV‐2 Pandemic Strains in Different Mouse Models
Journal of Medical Virology,
Год журнала:
2024,
Номер
96(11)
Опубликована: Ноя. 1, 2024
ABSTRACT
Elucidating
the
detailed
features
of
emerging
SARS‐CoV‐2
strains
both
in
vitro
and
vivo
is
indispensable
for
development
effective
vaccines
or
drugs
against
viral
infection.
We
thoroughly
characterized
virological
pathogenic
eight
different
pandemic
strains,
from
WT
strain
to
current
circulating
sublineage
EG.5.1,
vivo.
Besides
observed
Vero
E6
cells,
Omicron
variants,
BA.1
exhibited
enhanced
infectious
effects
upper
respiratory
tract
K18
human
angiotensin‐converting
enzyme
(ACE2)
(K18
hACE2)
transgenic
mice.
Both
XBB.1.9.1
EG.5.1
presented
stronger
tropism
brain,
which
could
be
main
reason
increased
lethal
on
In
addition,
pathogenesis
comparisons
among
all
these
viruses
C57BL/6JGpt
mice
indicated
that
variant
two
new
sublineages
possessed
dual
tropisms
mice,
were
further
confirmed
by
subsequent
bioinformatic
analyses
actual
affinity
comparison
between
RBDs
mouse
receptor
ACE2.
Furthermore,
immunocompromised
BKS‐db
found
more
susceptible
compared
revealed
infectivity
was
determined
its
host
immunocompetence.
Thus,
this
study
not
only
contributes
a
systematic
understanding
but
also
provides
insights
combat
potential
future
surges
variants.
Язык: Английский